Envirotainer Significantly Expands Global CryoSure® Network With New Singapore Station

Revolutionary -70°C cryogenic shipping now available across Asia and the Pacific

Stockholm, November 24, 2022: Envirotainer, the global market leader in secure cold chain solutions for shipment of pharmaceuticals, has opened a new CryoSure® station in Singapore. This significantly expands global availability of the ultra-cold solution for the transportation of medicines at -70°C. More>>

Etihad Cargo Achieves IATA CEIV Pharma Recertification for Pharmaceutical Logistics

Abu Dhabi, United Arab Emirates – Etihad Cargo, the cargo and logistics arm of Etihad Aviation Group, has been awarded Center of Excellence for Independent Validators (CEIV) Pharma recertification by the International Air Transport Association (IATA). The carrier is one of only 37 airlines to hold IATA CEIV Pharma certification globally. More>>

Shionogi, Active Citizenship Network and Meps Advocate for Urgent Policy Implementation in Eu Member States at Eu Parliament Event to Address the Growing Threat of Antimicrobial Resistance

OSAKA, Japan and AMSTERDAM, NL, 28 November 2022 – Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), held an event at the EU Parliament last week in the run-up to World Antimicrobial Awareness Week, joining forces with MEPs, Active Citizenship Network and MEPs Interest Group on "European Patients' Rights & Cross-Border Healthcare" to discuss initiatives to tackle AMR. The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue. More>>

Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality

7,500ft3 Facility Now Open to Evaluate Aerosolized Product Efficacy; Reduce Airborne Organisms, Viral Particles

7,500ft3 Facility Now Open to Evaluate Aerosolized Product Efficacy; Reduce Airborne Organisms, Viral Particles More>>

SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1

First findings from the study support the short- and long-term use of SPRAVATO® in adults living with treatment-resistant major depressive disorder in achieving remission and remaining relapse free1

November 23, 2022 -- BEERSE, Belgium--(BUSINESS WIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from ESCAPE-TRD, a long-term, comparative, randomised, open-label phase 3b clinical trial designed to evaluate the short- and long-term efficacy, safety and tolerability of flexibly dosed SPRAVATO® (esketamine nasal spray [NS]) compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), in adults with treatment-resistant major depressive disorder (TRD). The findings, presented today at the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Congress, showed that esketamine NS met its primary endpoint, demonstrating superior efficacy in achieving remission at Week 8 compared to quetiapine XR. The study also met its key secondary endpoint, demonstrating that not only did significantly more participants treated with esketamine NS compared to quetiapine XR achieve remission while on study treatment at Week 8, they also remained relapse free up to Week 32. More>>

Julia Forjanic Klapproth, Senior Partner at Trilogy Writing & Consulting receives the Harold Swanberg Distinguished Service Award 2022

Trilogy Writing & Consulting, a company specialised in regulatory writing, announced that one of its Senior Partners, Julia Forjanic Klapproth, was honored with the Harold Swanberg Distinguished Service Award during the American Medical Writers Association (AMWA) conference that took place in Denver, CO, in the beginning of November 2022. More>>

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation, and a world leader in the development and manufacture of advanced cell culture solutions for life science research, bioproduction, cell therapy manufacturing, and medical applications. The new facility is planned to ensure that FUJIFILM Irvine Scientific can meet increasing market demands for high quality cell culture media solutions. More>>

Tower’s latest container available for free demonstrations

Tower Cold Chain’s latest product for smaller pharmaceutical shipments, the KTEvolution container offering protection, security, and visibility in a small box, is now available for demonstration globally, at the company’s Centres of Excellence in the EMEA, APAC and Americas regions. More>>

uMotif Announces First New Validated Innovation in eCOA/ePRO Since Paper Instruments Were Deployed on Smartphones

Patent-protected Motif data capture interface proven as equivalent method to capture Patient Reported Outcome and eDiary data, eliminates reliance on text-based instruments, in study with 55 participants in 2 randomized groups conducted by SAFIRA Clinica

Patent-protected Motif data capture interface proven as equivalent method to capture Patient Reported Outcome and eDiary data, eliminates reliance on text-based instruments, in study with 55 participants in 2 randomized groups conducted by SAFIRA Clinical Research at Dublin City University More>>

Blood Tests May Prevent Relapse in Breast Cancer Patients

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients wil

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients will relapse, years before it’s shown on a scan - treatment can then be altered to try and prevent relapse from happening. There are currently no effective tests to establish which patients are at risk of relapse after previous treatment for breast cancer. More>>